GleamWall
中文EN

ELAB PMGC Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—

Returns

ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$590,084—
Cost of revenue$404,770—
Gross profit$185,314—
R&D expense$147,010$104,654
SG&A expense$2.24M$1.09M
Interest expense$257,630$735,197
Pretax income-$7.75M-$4.02M
Income tax$30,972—
Net income-$7.75M-$6.25M
EPS (diluted)——
Balance sheet
Cash & equivalents$5.40M$3.98M
Short-term investments$572,054—
Receivables$245,423$5,276
Inventory$95,098—
Current assets$6.87M$6.05M
PP&E, net$885,520$1,087
Goodwill$977,774—
Intangibles$2.89M$2.80M
Total assets$12.87M$8.99M
Current liabilities$3.94M$1.80M
Total liabilities$5.03M$2.33M
Shareholders' equity$7.84M$6.66M
Shares outstanding8,0705,226
Cash flow statement
Operating cash flow-$5.93M-$5.49M
Capital expenditure$442,255$9,160
Free cash flow-$6.38M-$5.50M
Investing cash flow-$2.77M-$610,564
Financing cash flow$10.12M$6.76M
Depreciation & amortization$96,145$546
Stock-based compensation-$19,160$97,167

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.